Table of Contents Author Guidelines Submit a Manuscript
Pulmonary Medicine
Volume 2011 (2011), Article ID 257496, 11 pages
http://dx.doi.org/10.1155/2011/257496
Review Article

Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease

1Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USA
2Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine, 4150 V Street, Suite 3400, Sacramento, CA 95817, USA

Received 25 September 2010; Revised 21 January 2011; Accepted 22 February 2011

Academic Editor: Stefano Centanni

Copyright © 2011 Rokhsara Rafii et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Buhl and S. G. Farmer, “Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 2, no. 1, pp. 83–93, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. T. E. Albertson, S. Louie, and A. L. Chan, “The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis,” Journal of the American Geriatrics Society, vol. 58, no. 3, pp. 570–579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. De Marco, S. Accordini, I. Cerveri et al., “Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 1, pp. 32–39, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. Global Initiative for Chronic Obstructive Lung Disease, “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease,” NHLBI/WHO Workshop Report, National Heart, Lung, and Blood Institute, Bethesda, Md, USA, 2001, http://www.goldcopd.com/. View at Google Scholar
  5. U.S. Environmental Protection Agency, “Chronic obstructive pulmonary disease prevalence and mortality,” December 2009, http://cfpub.epa.gov/eroe/index.
  6. A. Jemal, E. Ward, Y. Hao, and M. Thun, “Trends in the leading causes of death in the United States, 1970–2002,” Journal of the American Medical Association, vol. 294, no. 10, pp. 1255–1259, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. M. Mannino, D. M. Homa, L. J. Akinbami, E. S. Ford, and S. C. Redd, “Chronic obstructive pulmonary disease surveillance–United States, 1971-2000,” Morbidity and Mortality Weekly Report, vol. 51, no. 6, pp. 1–16, 2002. View at Google Scholar
  8. Centers for Disease Control, “Deaths from chronic obstructive pulmonary disease, United States 2000–2005,” Morbidity and Mortality Weekly Report, vol. 57, no. 45, pp. 1229–1232, 2008. View at Google Scholar
  9. N. R. Anthonisen, M. A. Skeans, R. A. Wise, J. Manfreda, R. E. Kanner, and J. E. Connett, “The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial,” Annals of Internal Medicine, vol. 142, no. 4, pp. 233–239, 2005. View at Google Scholar
  10. R. L. Berger, M. M. DeCamp, G. J. Criner, and B. R. Celli, “Lung volume reduction therapies for advanced emphysema: an update,” Chest, vol. 138, no. 2, pp. 407–417, 2010. View at Publisher · View at Google Scholar
  11. P. M. A. Calverley, J. A. Anderson, B. Celli et al., “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 356, no. 8, pp. 775–789, 2007. View at Publisher · View at Google Scholar · View at PubMed
  12. D. P. Tashkin, B. Celli, S. Senn et al., “A 4-year trial of tiotropium in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1543–1554, 2008. View at Publisher · View at Google Scholar · View at PubMed
  13. B. Celli, M. Decramer, S. Kesten, D. Liu, S. Mehra, and D. P. Tashkin, “Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 10, pp. 948–955, 2009. View at Publisher · View at Google Scholar
  14. C. Vogelmeier, P. Kardos, S. Harari, S. J. M. Gans, S. Stenglein, and J. Thirlwell, “Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study,” Respiratory Medicine, vol. 102, no. 11, pp. 1511–1520, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. Bone, M. Boyars, S. R. Braun et al., “In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group,” Chest, vol. 105, no. 5, pp. 1411–1419, 1994. View at Google Scholar
  16. N. Gross, D. Tashkin, R. Miller, J. Oren, W. Coleman, and S. Linberg, “Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease,” Respiration, vol. 65, no. 5, pp. 354–362, 1998. View at Publisher · View at Google Scholar
  17. T. S. Lapperre, J. B. Snoeck-Stroband, M. M. E. Gosman et al., “Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial,” Annals of Internal Medicine, vol. 151, no. 8, pp. 517–527, 2009. View at Google Scholar
  18. E. D. Telenga, H. A. M. Kerstjens, D. S. Postma, N. H. Ten Hacken, and M. van den Berge, “Inhaled corticosteroids in chronic obstructive pulmonary disease: a review,” Expert Opinion on Pharmacotherapy, vol. 11, no. 3, pp. 405–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Kliber, L. D. Lynd, and D. D. Sin, “The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease,” Respiratory Research, vol. 11, article 56, 2010. View at Publisher · View at Google Scholar
  20. M. B. Drummond, E. C. Dasenbrook, M. W. Pitz, D. J. Murphy, and E. Fan, “Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 300, no. 20, pp. 2407–2416, 2008. View at Publisher · View at Google Scholar
  21. S. Singh, A. V. Amin, and Y. K. Loke, “Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease,” Archives of Internal Medicine, vol. 169, no. 3, pp. 219–229, 2009. View at Publisher · View at Google Scholar
  22. R. ZuWallack, “The nonpharmacologic treatment of chronic obstructive pulmonary disease: advances in our understanding of pulmonary rehabilitation,” Proceedings of the American Thoracic Society, vol. 4, no. 7, pp. 549–553, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. L. Nici, C. Donner, E. Wouters et al., “American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 12, pp. 1390–1413, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. K. A. Hardin, F. Meyers, and S. Louie, “Integrating palliative care in severe chronic obstructive lung disease,” COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 5, no. 4, pp. 207–220, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. T. Claessens, J. Lynn, Z. Zhong et al., “Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments,” Journal of the American Geriatrics Society, vol. 48, supplement 5, pp. S146–S153, 2000. View at Google Scholar
  26. P. A. Kvale, W. A. Conway, and E. O. Coates, “Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial,” Annals of Internal Medicine, vol. 93, no. 3, pp. 391–398, 1980. View at Google Scholar · View at Scopus
  27. C. Stuart-Harris, J. M. Bishop, and T. J. H. Clark, “Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema,” The Lancet, vol. 1, no. 8222, pp. 681–686, 1981. View at Google Scholar
  28. A. J. Crockett, J. M. Cranston, J. R. Moss, and J. H. Alpers, “Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting,” Internal Medicine Journal, vol. 31, no. 8, pp. 448–454, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. C. Hogg, F. Chu, S. Utokaparch et al., “The nature of small-airway obstruction in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 350, no. 26, pp. 2645–2653, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. P. K. Jeffery, “Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 1, no. 3, pp. 176–183, 2004. View at Google Scholar · View at Scopus
  31. K. F. Rabe, E. D. Bateman, D. O'Donnell, S. Witte, D. Bredenbröker, and T. D. Bethke, “Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial,” The Lancet, vol. 366, no. 9485, pp. 563–571, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. C. H. Compton, J. Gubb, R. Nieman et al., “Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study,” The Lancet, vol. 358, no. 9278, pp. 265–270, 2001. View at Publisher · View at Google Scholar · View at PubMed
  33. S. I. Rennard, N. Schachter, M. Strek, K. Richard, and O. Amit, “Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4,” Chest, vol. 129, no. 1, pp. 56–66, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. A. Giembycz, “An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease,” British Journal of Clinical Pharmacology, vol. 62, no. 2, pp. 138–152, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. A. McIvor, “Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors,” European Respiratory Review, vol. 16, no. 105, pp. 105–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Calverley, K. F. Rabe, U.-M. Goehring, S. Kristiansen, L. M. Fabbri, and F. J. Martinez, “Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials,” The Lancet, vol. 374, no. 9691, pp. 685–694, 2009. View at Publisher · View at Google Scholar
  37. L. M. Fabbri, P. M. Calverley, J. L. Izquierdo-Alonso et al., “Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials,” The Lancet, vol. 374, no. 9691, pp. 695–703, 2009. View at Publisher · View at Google Scholar
  38. The Medical News, “FDA issues complete response letter for roflumilast NDA,” May 2010, http://www.news-medical.net/news/20100518/.
  39. “Gen: genetic engineering and biotechnology news,” July 2010, http://www.genengnews.com/.
  40. P. N. Dekhuijzen and W. J. van Beurden, “The role for N-acetylcysteine in the management of COPD,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 1, no. 2, pp. 99–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. M. M. E. Bridgeman, M. Marsden, W. MacNee, D. C. Flenley, and A. P. Ryle, “Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine,” Thorax, vol. 46, no. 1, pp. 39–42, 1991. View at Google Scholar · View at Scopus
  42. M. Linden, E. Wieslander, A. Eklund, K. Larsson, and R. Brattsand, “Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers,” European Respiratory Journal, vol. 1, no. 7, pp. 645–650, 1988. View at Google Scholar · View at Scopus
  43. G. C. Riise, I. Qvarfordt, S. Larsson, V. Eliasson, and B. A. Andersson, “Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro,” Respiration, vol. 67, no. 5, pp. 552–558, 2000. View at Google Scholar · View at Scopus
  44. E. M. Grandjean, P. Berthet, R. Ruffmann, and P. Leuenberger, “Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials,” Clinical Therapeutics, vol. 22, no. 2, pp. 209–221, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Stey, J. Steurer, S. Bachmann, T. C. Medici, and M. R. Tramer, “The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review,” European Respiratory Journal, vol. 16, no. 2, pp. 253–262, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Decramer, M. Rutten-Van Mölken, P. N. R. Dekhuijzen et al., “Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial,” The Lancet, vol. 365, no. 9470, pp. 1552–1560, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. R. Zuin, A. Palamidese, R. Negrin, L. Catozzo, A. Scarda, and M. Balbinot, “High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease,” Clinical Drug Investigation, vol. 25, no. 6, pp. 401–408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. V. M. Keatings, P. D. Collins, D. M. Scott, and P. J. Barnes, “Differences in interleukin-8 and tumor necrosis facfor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 2, pp. 530–534, 1996. View at Google Scholar · View at Scopus
  49. I. De Godoy, M. Donahoe, W. J. Calhoun, J. Mancino, and R. M. Rogers, “Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 2, pp. 633–637, 1996. View at Google Scholar · View at Scopus
  50. S. I. Rennard, C. Fogarty, S. Kelsen et al., “The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 9, pp. 926–934, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell, “Efficacy and safety of a monoclonal antibody recognizing lnterleukin-8 in COPD: a pilot study,” Chest, vol. 126, no. 3, pp. 926–934, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. F. Donohue, “COPD management: current therapies and novel treatment approaches,” Journal COPD Management, March 2006. View at Google Scholar
  53. S. Gompertz and R. A. Stockley, “A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD,” Chest, vol. 122, no. 1, pp. 289–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. F. J. Martinez, J. L. Curtis, and R. Albert, “Role of macrolide therapy in chronic obstructive pulmonary disease,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 3, no. 3, pp. 331–350, 2008. View at Google Scholar · View at Scopus
  55. T. A. R. Seemungal, T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, R. J. Sapsford, and J. A. Wedzicha, “Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 11, pp. 1139–1147, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. I. Basyigit, F. Yildiz, S. K. Ozkara, E. Yildirim, H. Boyaci, and A. Ilgazli, “The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data,” Annals of Pharmacotherapy, vol. 38, no. 9, pp. 1400–1405, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. D. Banerjee, D. Honeybourne, and O. A. Khair, “The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial,” Treatments in Respiratory Medicine, vol. 3, no. 1, pp. 59–65, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. W. Janssens, R. Bouillon, B. Claes et al., “Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene,” Thorax, vol. 65, no. 3, pp. 215–220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. P. N. Black and R. Scragg, “Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey,” Chest, vol. 128, no. 6, pp. 3792–3798, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. L. Førli, J. Halse, E. Haug et al., “Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease,” Journal of Internal Medicine, vol. 256, no. 1, pp. 56–62, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. A. Fishman, F. Martinez, K. Naunheim et al., “A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema,” The New England Journal of Medicine, vol. 348, no. 21, pp. 2059–2073, 2003. View at Publisher · View at Google Scholar · View at PubMed
  62. G. J. Criner and A. L. Sternberg, “National emphysema treatment trial: the major outcomes of lung volume reduction surgery in severe emphysema,” Proceedings of the American Thoracic Society, vol. 5, no. 4, pp. 393–405, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. B. J. Make and A. M. Fein, “Is volume reduction surgery appropriate in the treatment of emphysema? No,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 4, pp. 1205–1207, 1996. View at Google Scholar · View at Scopus
  64. S. Sabanathan, J. Richardson, and S. Pieri-Davies, “Bronchoscopic lung volume reduction,” Journal of Cardiovascular Surgery, vol. 44, no. 1, pp. 101–108, 2003. View at Google Scholar · View at Scopus
  65. A. Ernst and D. Anantham, “Invasive procedures for emphysema,” Americal Colllege of Chest Physicians, PCCSU, vol. 24, no. 12, 2010. View at Google Scholar
  66. C. K. Choong, P. T. Macklem, J. A. Pierce et al., “Airway bypass improves the mechanical properties of explanted emphysematous lungs,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 9, pp. 902–905, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. H. F. Lausberg, K. Chino, G. A. Patterson et al., “Bronchial fenestration improves expiratory flow in emphysematous human lungs,” Annals of Thoracic Surgery, vol. 75, no. 2, pp. 393–398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. E. A. Rendina, T. De Giacomo, F. Venuta et al., “Feasibility and safety of the airway bypass procedure for patients with emphysema,” Journal of Thoracic and Cardiovascular Surgery, vol. 125, no. 6, pp. 1294–1299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. C. K. Choong, L. Phan, P. Massetti et al., “Prolongation of patency of airway bypass stents with use of drug-eluting stents,” Journal of Thoracic and Cardiovascular Surgery, vol. 131, no. 1, pp. 60–64, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. P. F. G. Cardoso, G. I. Snell, P. Hopkins et al., “Clinical application of airway bypass with paclitaxel-eluting stents: early results,” Journal of Thoracic and Cardiovascular Surgery, vol. 134, no. 4, pp. 974–981, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. I. Y. P. Wan, T. P. Toma, D. M. Geddes et al., “Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients,” Chest, vol. 129, no. 3, pp. 518–526, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. D. E. Wood, R. J. McKenna, R. D. Yusen et al., “A multicenter trial of an intrabronchial valve for treatment of severe emphysema,” Journal of Thoracic and Cardiovascular Surgery, vol. 133, no. 1, pp. 65–e2, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. Emphasys Medical, Inc., “Executive Summary, P070025, Zephyr Endobronchial Valve System. U.S. P070025,” in Presented at: Anesthesiology and Respiratory Therapy Devices Panel, Gathersburg, Md, USA, December 2008.
  74. E. P. Walker, “FDA advisers recommend rejection of airway valve for emphysema,” December 2008, http://www.medpagetoday.com/.
  75. S. C. Springmeyer, C. T. Bolliger, T. K. Waddell, X. Gonzalez, and D. E. Wood, “Treatment of heterogeneous emphysema using the spiration IBV valves,” Thoracic Surgery Clinics, vol. 19, no. 2, pp. 247–253, 2009. View at Publisher · View at Google Scholar · View at PubMed
  76. N. S. Hopkinson, T. P. Toma, D. M. Hansell et al., “Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 453–460, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. S. C.S. Chung, M. J. Peters, S. Chen, L. Emmett, and A. J. Ing, “Effect of unilateral endobronchial valve insertion on pulmonary ventilation and perfusion: a pilot study,” Respirology, vol. 15, no. 7, pp. 1079–1083, 2010. View at Publisher · View at Google Scholar
  78. E. P. Ingenito, J. J. Reilly, S. J. Mentzer et al., “Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 2, pp. 295–301, 2001. View at Google Scholar · View at Scopus
  79. J. Reilly, G. Washko, V. Pinto-Plata et al., “Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema,” Chest, vol. 131, no. 4, pp. 1108–1113, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. G. J. Criner, V. Pinto-Plata, C. Strange et al., “Biologic lung volume reduction in advanced upper lobe emphysema phase 2 results,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 9, pp. 791–798, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus